Multinationals’ China Trial Strategies Shift As Industry Adapts
This article was originally published in The Pink Sheet Daily
Executive Summary
2013 marked a new low for clinical trial approvals in China. A compliance crackdown that has brought caution to multinational firms in particular has added to fast-paced changes evident in the industry, says a clinical research insider with years of experience at multinational drug makers in China.